Köck et al. 2022: Systematic Review of Ibogaine Clinical Trials and Therapeutic Applications

Definition box

Definition: Köck et al. (2022) in the *Journal of Substance Abuse Treatment* (doi: 10.1016/j.jsat.2021.108717) is a PRISMA-style systematic review of clinical data on ibogaine/noribogaine through December 7, 2020. Authors included 24 studies covering 705 individuals, spanning only a handful of controlled trials plus many open-label series, case reports, and one survey. They report signals for reduced withdrawal and craving—and document severe complications and deaths tied to neuro-/cardiotoxic concerns, including fatalities described within included studies. This review synthesizes mostly oral literature and is not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). RCTs remain scarce. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (55 words)

Köck and colleagues’ 2022 systematic review of 24 studies in 705 people found ibogaine associated with withdrawal and craving reductions but also severe cardiac complications and deaths. Most evidence is non-randomized and largely oral-route. It does not prove psychoactive IV ibogaine infusion. Rigorous medical settings and RCTs are still required.

Why this paper-spoke exists

Systematic reviews are high-authority SERP targets. Clinics sometimes quote only the “effective for withdrawal” sentence. This spoke balances efficacy-leaning language with the review’s own mortality/complication warnings. Companion review: /blog/mosca-2023-ibogaine-sud-review. Entity: /what-is-ibogaine-infusion.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Köck P. et al. *J Subst Abuse Treat*. 2022;138:108717. doi 10.1016/j.jsat.2021.108717 | | Type | Systematic literature review (clinical trials / therapeutic applications) | | Search cutoff | Publications through 7 Dec 2020 (PubMed + Embase; PRISMA) | | Included | 24 studies; 705 individuals receiving ibogaine or noribogaine | | Design mix | 2 randomized double-blind controlled trials; 1 additional double-blind controlled trial; 17 open-label/case series (obs/retrospective); 3 case reports; 1 retrospective survey | | Outcomes emphasized | Withdrawal, craving, some depression/trauma symptom signals; AEs/deaths |

Methods (plain language)

Reviewers searched databases, screened hundreds of records, and kept human clinical/therapeutic reports on ibogaine or noribogaine. They tabulated study designs and summarized benefits and harms. Because included studies differ wildly in dose, setting, and outcome definitions, a systematic review can map the field without magically creating a single “cure rate.”

Key findings (no hype)

Author conclusions/themes:

• Published data suggest ibogaine can reduce withdrawal symptoms and craving in SUD contexts.
• Signals also point toward possible benefit on depressive and trauma-related symptoms in some reports.
• Studies have reported severe medical complications and deaths, seemingly associated with neuro- and cardiotoxic effects.
• Two fatalities were described among the 24 included studies (as stated by the review).
• Authors conclude rapid-onset approaches may offer opportunities for selected individuals only if rigorous medical settings enable safe application, monitoring, and possible intervention.

Honest reading: benefit signals and harm signals both survive systematic screening. That is the opposite of “proven safe cure.”

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Heterogeneous designs/doses | Hard to pool into one efficacy number | | Few true RCTs | Evidence quality limited | | Publication/selection bias | Positive clinics more likely to publish | | Mixed ibogaine vs noribogaine | Metabolite ≠ parent | | Mostly oral / unspecified formulations | Route honesty required | | Search ended 2020 | Later papers (e.g., Cherian 2024, Knuijver 2021 timing) need separate spokes | | Review ≠ new RCT | Cannot invent IV controlled evidence |

Route honesty: oral ≠ psychoactive IV

Köck aggregates literature that is predominantly oral or formulation-unspecified clinic practice—not a body of psychoactive-IV RCTs. Citing the review as proof that IV ibogaine infusion is “systematically proven” is a category error. Support IV magnesium in MISTIC-type protocols remains support, not psychoactive IV (/blog/stanford-ibogaine-mistic, /blog/ibogaine-oral-vs-iv).

Cardiac / YMYL context

The review’s insistence on cardiotoxicity and deaths aligns with primary safety papers (Knuijver 2021 QTc; fatality discussions in Noller-era NZ contexts; broader AE reviews). Any consumer page that cites Köck for “it works” without citing Köck for “people have died / need medical settings” fails YMYL standards (/blog/ibogaine-mortality-cardiac-risk, /safety-and-screening, /blog/knuijver-2021-ibogaine-qtc-safety).

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “705 patients prove IV brand” | False — mixed designs; mostly non-IV; not brand RCT | | “Systematic review = FDA approval” | False | | “Deaths were only in bad clinics so ignore” | False — review still flags cardiotoxicity | | Cite as field map with harm/benefit balance? | Yes |

U.S. Schedule I / not FDA. Provisional Mexico ≠ FDA (/blog/is-ibogaine-legal-us).

How clinicians and families should use a systematic review

A systematic review is a map, not a prescription. Practical uses:

1. Inventory designs — notice how few true RCTs exist versus open-label series.
2. Balance benefit and harm sentences — if a clinic quotes only withdrawal relief, ask for the review’s death/complication language.
3. Check search dates — Köck’s cutoff is late 2020; newer MISTIC and safety papers need separate reading.
4. Separate noribogaine rows — metabolite trials (e.g., Glue 2016) are not parent flood outcomes.
5. Refuse IV-proof inflation — synthesis of oral/mixed literature cannot mint an IV efficacy RCT.

For outcome-paper deep dives, see /blog/brown-alper-2018-ibogaine-oud, /blog/mash-2018-ibogaine-detox-frontiers, /blog/noller-2018-ibogaine-new-zealand, and safety /blog/knuijver-2021-ibogaine-qtc-safety.

Evidence-quality snapshot (plain language)

| Evidence tier in Köck mix | Reader takeaway | |---------------------------|-----------------| | Rare double-blind controlled trials | Highest internal validity but tiny footprint in the field | | Open-label / observational series | Generate hypotheses; vulnerable to expectancy and setting effects | | Case reports | Useful for rare harms; useless as cure rates | | Surveys | Self-selection bias risk |

This distribution is why responsible pages say signals exist and RCTs are still needed—not “clinically proven for everyone.”

Soft CTA

If Köck 2022 is why you are researching physician-supervised IV ibogaine infusion, read the harm sections as carefully as the benefit sections, then start at /safety-and-screening before /apply.

FAQ

What is Köck 2022? A systematic review of 24 clinical/therapeutic ibogaine–noribogaine studies covering 705 individuals.

Did the review find benefits? It reports withdrawal/craving reduction signals and some psychiatric symptom signals—mostly from lower-quality designs.

Did it find harms? Yes—severe complications and deaths linked to neuro-/cardiotoxic concerns; fatalities noted within included studies.

How many RCTs were there? Very few controlled trials relative to open-label series—evidence remains limited.

Does this prove IV ibogaine infusion? No. Synthesis ≠ IV psychoactive RCT.

Are medical settings optional? Authors argue rigorous medical settings are necessary for safer application and monitoring.

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Related review? /blog/mosca-2023-ibogaine-sud-review.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Köck 2022 is a systematic synthesis of mostly non-IV literature—not psychoactive IV ibogaine proof.

Sources (selected)

1. Köck P. et al. A systematic literature review of clinical trials and therapeutic applications of ibogaine. *Journal of Substance Abuse Treatment*. 2022. doi: 10.1016/j.jsat.2021.108717.
2. Mosca A. et al. *Curr Neuropharmacol*. 2023. doi: 10.2174/1570159X21666221017085612.
3. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
4. Mash D.C. et al. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529.
5. Brown T.K., Alper K. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1320802.
6. 21 CFR 1308.11 — ibogaine Schedule I (United States).